Lakewood-Amedex Biotherapeutics Inc., based in Sarasota, Florida, recently showcased its unique Bisphosphocin® platform and primary clinical candidate, Nu-3, as novel methods to combat microbial infections and the potential development of resistance. The company, listed on NASDAQ, emphasized the innovation behind these approaches during their event on July 7, 2026.